ZimVie (NASDAQ:ZIMV – Free Report) had its price target increased by Needham & Company LLC from $20.00 to $23.00 in a report issued on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
ZimVie Stock Down 15.2 %
ZIMV stock opened at $17.30 on Friday. ZimVie has a 12 month low of $6.52 and a 12 month high of $22.40. The firm has a 50 day simple moving average of $18.05 and a 200 day simple moving average of $17.53. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.68 and a quick ratio of 2.23.
ZimVie (NASDAQ:ZIMV – Get Free Report) last released its earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter. ZimVie had a negative net margin of 63.84% and a positive return on equity of 2.09%. The business had revenue of $116.81 million during the quarter. During the same period in the prior year, the company earned $0.17 earnings per share. On average, research analysts anticipate that ZimVie will post 0.63 EPS for the current year.
Institutional Trading of ZimVie
About ZimVie
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Read More
- Five stocks we like better than ZimVie
- Consumer Discretionary Stocks Explained
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Breakout Stocks: What They Are and How to Identify Them
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Are Penny Stocks a Good Fit for Your Portfolio?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.